Multiplexed ultra fast and sensitive bioagent assays- Diagnostics

快速、灵敏和特定于试剂的测试是支持 生物制剂诊断设备的发展。今天广泛使用的技术，如RT-PCR， 要么是特定于试剂但不够快，要么需要在现场采集样本进行分析 在一段时间和一段距离之外的实验室中通过一套方法进行评估。即使是在 在实验室，收集的样本仍可能需要数小时才能单独进行分析。目前，还没有平台 商业化的技术可以检测特定药物在该领域的单拷贝数 在一分钟内，或者确实允许在实验室进行快速高通量分析单份灵敏度 布景。 在这方面，Geddes实验室在过去两年里一直在开发一种平台技术 这可能会改变我们考虑检测生物制剂存在的方式。微波炉- 加速金属增强荧光(MAMEF)结合金属增强荧光的应用 (MEF)将荧光信号放大多个数量级，显著提高 分析灵敏度，使用低功率聚焦微波来动态加速生物反应 (化验)在几秒钟内完成，不会使化验成分变性。在礼物下面 Marce Development奖，Geddes小组开发了一种高度特异的炭疽病毒检测方法， 可以在20秒内检测到100份炭疽杆菌基因组。另外还有5秒，孢子和 对于营养有机体，裂解技术还允许收集DNA，因为它快速 测试，总样品准备和分析运行时间不到一分钟。 在此次MARCE-2更新中，MAMEF技术将成为 诊断组，总的具体目标是：1)支持其他MARCE核心并采用 MAMEF技术帮助其他项目，例如疫苗挑战研究等，2)继续 为Marce核心利益的其他生物制剂开发MAMEF平台，以及 将MAMEF技术开发成多路复用平台，能够检测到许多 生物制剂同时或实际上同时高通量筛选多个样本和 3)寻求技术的商业化。

Fast, sensitive and agent specific tests are the fundamental underlying technologies behind the development of Bioagent diagnostic devices. Technologies which are widely used today such as RT-PCR, are either agent specific but not fast enough, or require sample collection in the field for analytical evaluation by a suite of approaches in a laboratory both some time and distance away. Even when in the laboratory, the collected samples can still take many hrs to analyze individually. At present, no platform technology is available commercially, which can detect single copy numbers of a specific agent in the field within one minute, or indeed allow fast high-throughput analysis single-copy sensitivity in a laboratory setting. In this regard the Geddes laboratories have for the last 2 years been developing a platform technology which threatens to change the way we consider testing for the presence of Bioagents. Microwave- Accelerated Metal-Enhanced Fluorescence (MAMEF) combines the use of Metal-Enhanced Fluorescence (MEF) to amplify fluorescence signatures up to many orders of magnitude which significantly improves assay sensitivity, with the use of low power focused microwaves to kinetically accelerate bio-reactions (assays) to completion within seconds, without denaturation of the assay components. Under a present MARCE developmental award, the Geddes group has developed a highly specific Anthrax assay which can detect <100 copies of the Anthrax PA genome within 20 seconds. In addition a 5 second, spore and the vegetative organism, lysing technology additionally allows for the collection of DNA for its rapid testing, with a total sample preparation and assay run time under one minute. In this MARCE-2 renewal, the MAMEF technology is to stand as a central hub technology for the Diagnostics group, with the general specific aims of: 1) Supporting other MARCE cores and adopting the MAMEF technology to aid other programs, e.g. in vaccine challenge studies etc, 2) Continued development of the MAMEF platform for other bioagents at the core interest of the MARCE, and the development of the MAMEF technology into a multiplexed platform, capable of detecting either numerous bioagents simultaneously or indeed the high-throughput screening of many samples simultaneously and 3) to seek commercialization of the technologies.